Avalo Therapeutics CFO Christopher Ryan Sullivan disposes of 12,394 common shares for $202,436.79
Avalo Therapeutics CFO Christopher Ryan Sullivan sold 12,394 common shares at USD 16.33 on Sep. 16, 2026. Sale followed the exercise of stock options for 12,394 shares at USD 9.88. Directly held common shares fell to 39,900. * Directly held stock options rose to 83,848. Disclaimer: This news brief was created by Public